ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): Outcome and long-term follow-up of 50 patients from a single polish centre

Clinical and Experimental Rheumatology

Volumn 32, Issue SUPPL.82, 2014, Pages

  Sokołowska, Barbara ^a   Szczeklik, Wojciech ^a   Włudarczyk, Anna ^a   Kuczia, Paweł ^a   Jakieła, Bogdan ^a   Gasior, Jolanta ^a   Bartyzel, Sylwia ^a   Rewerski, Piotr ^a   Musiał, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ANCA associated vasculitis; Anti neutrophil cytoplasmic antibody; Anti neutrophil cytoplasmicantibody associated vasculitis; Eosinophilic granulomatous vasculitis

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MONTELUKAST; NEUTROPHIL CYTOPLASMIC ANTIBODY; STEROID;

ADULT; ARTICLE; ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIVE FACTOR SCORE SCALE; FOLLOW UP; HEART DISEASE; HUMAN; KIDNEY DISEASE; LONG TERM CARE; MALE; MONONEUROPATHY MULTIPLEX; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; PHENOTYPE; POLAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN DISEASE; TERTIARY CARE CENTER;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; COHORT STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PHENOTYPE; POLAND; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901951681     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. MAHR A, MOOSIG F, NEUMANN T et al.: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol 2014; 26: 16-23.
2. TALARICO R, BALDINI C, Della ROSSA A, CARLI L, TANI C, BOMBARDIERI S. Systemic vasculitis: a critical digest of the recent literature. Clin Exp Rheumatol 2013; 31 (Suppl 75): S84-8.
3. SZCZEKLIK W, JAKIEŁA B, ADAMEK D, MUSIAŁ J: Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol 2013; 44: 39-50.
4. WATTS RA, LANE S, SCOTT DG: What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005; 19: 191-207.
5. JAKIELA B, SZCZEKLIK W, SOKOLOWSKA B et al.: Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg-Strauss syndrome. Rheumatology (Oxford) 2009; 48: 1202-7.
6. JAKIELA B, SZCZEKLIK W, PLUTECKA H et al.: Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford) 2012; 51: 1887-93.
7. JAKIELA B, SANAK M, SZCZEKLIK W et al.: Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011; 29 (Suppl. 64): S23-34.
8. DUNOGUÉ B, PAGNOUX C, GUILLEVIN L: Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 2011; 32: 298-309.
9. VAGLIO A, MOOSIG F, ZWERINA J: Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 2012; 24: 24-30.
10. HEALY B, BIBBY S, STEELE R, WEATHERALL M, NELSON H, BEASLEY R: Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol 2013; 131: 571-6.e1-6
11. SINICO RA, DI TOMA L, MAGGIORE U et al.: Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
12. SABLE-FOURTASSOU R, COHEN P, MAHR A et al.: Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-8.
13. BALDINI C, Della ROSSA A, GROSSI S et al.: [Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre]. Reumatismo 2009; 61: 118-24.
14. CHURG J, STRAUSS L: Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 277-301.
15. CHUMBLEY LC, HARRISON EG Jr, DEREMEE RA: Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52: 477-84.
16. LANHAM JG, ELKON KB, PUSEY CD, HUGHES GR: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65-81.
17. ABU-SHAKRA M, SMYTHE H, LEWTAS J, BADLEY E, WEBER D, KEYSTONE E: Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum 1994; 37: 1798-803.
18. GUILLEVIN L, COHEN P, GAYRAUD M, LHOTE F, JARROUSSE B, CASASSUS P: Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37.
19. SOLANS R, BOSCH JA, PÉREZ-BOCANEGRA C et al.: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford). 2001; 40: 763-71
20. Della ROSSA A, BALDINI C, TAVONI A et al.: Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41: 1286-94.
21. COMARMOND C, PAGNOUX CH, KHELLAF M et al.: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group Cohort. Arthritis Rheum 2013; 65: 270-81.
22. MOOSIG F, BREMER JP, HELLMICH B et al.: A vasculitis center based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72: 1011-7.
23. MASI AT, HUNDER GG, LIE JT et al.: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-100.
24. GUILLEVIN L, PAGNOUX C, SEROR R et al.: French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90: 19-27.
25. National Aasthma Eeducation and Prevention Program (National Hheart Llung and Blood Iinstitute): Third Expert Panel on the Management of Asthma. Guidelines for the diagnosis and management of asthma: summary report 2007. Bethesda, MD: U.S. Department of Health and Human Services, National Institues of Health, National Heart, Lung, and Blood Institute, 2008.
26. MUKHTYAR C, LEE R, BROWN D et al.: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-32.
27. SZCZEKLIK W, MISZALSKI-JAMKA T, MASTALERZ L et al.: Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75: 649-55.
28. MARMURSZTEJN J, VIGNAUX O, COHEN P et al.: Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol 2009; 27 (Suppl. 52): S70-6.
29. SZCZEKLIK W, SOKOŁOWSKA BM, ZUK J et al.: The course of asthma in Churg-Strauss syndrome. J Asthma 2011; 48: 183-7.
30. SAMSON M, PUECHAL X, DEVILLIERS HERVE et al.: Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013; 43: 60-9.
31. LOO KL, RAMACHANDRAN R, CHOW SK, GOH EM, YEAP SS: Mononeuritis in Churg-Strauss syndrome in Asians responding to intravenous cyclophosphamide. Rheumatology (Oxford) 2004; 43: 251-2.
32. HOI AY, MORAND EF: Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. Rheumatology (Oxford) 2003; 42: 390-1.
33. SOKOŁOWSKA B, SZCZEKLIK W, MASTALERZ L et al.: Effect of delayed diagnosis on disease course and management of Churg-Strauss syndrome: a retrospective study. Clin Rheumatol 2013; 32: 349-54.